Clinical Study on the Efficacy and Safety of Hydromorphone for ICU Analgesia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorAffiliated Hospital of Nantong University
About this trial
This study is a prospective, single-center clinical study to evaluate the advantages, extensibility and safety of hydromorphone as an analgesic drug in ICU, and to compare it with remifentanil, a traditional sedative drug. These conclusions can guide us to understand the characteristics of analgesic drugs, carry out appropriate pain management, improve the status of ICU patients, and improve the quality of life of patients.
Eligibility criteria
Qualifiers
Age ≥18 years and ≤75 years;
For patients requiring sedation and analgesia in ICU, invasive mechanical ventilation time is expected to be ≥24 hours;
Obtain informed consent from patients or family members.
Disqualifiers
Under 18 years of age, or over 75 years of age;
pregnancy or breastfeeding;
Known or suspected allergy to opioids (e.g., fentanyl, remifentanil, hydromorphone), butorphanol, midazolam.
General anesthesia surgery within 48 hours;
Trial design
Treatments tested in this trial
- no-intervention
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov